Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785925 · ClinicalTrials.gov registry record · Phase 2
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT03785925 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 192 participants.
The verdict
NCT03785925, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Bempegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785925
The ClinicalTrials.gov registry entry for NCT03785925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03785925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785925 about?
NCT03785925 is a clinical study titled "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer". The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.
What is the current status of trial NCT03785925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2019-04-29. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03785925?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Bempegaldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03785925?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.